Andrea Vethencourt

Barcelona, CT 08908, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization Beyond Quantification.

Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization Beyond Quantification.

Journal: Cancers

Published: May 04, 2026

Lymph node stromal topology as a hidden regulator of breast cancer outcome: commentary on reticular network analysis†.

Lymph node stromal topology as a hidden regulator of breast cancer outcome: commentary on reticular network analysis†.

Journal: The Journal of pathology

Published: April 29, 2026

Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline.

Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline.

Journal: Cancers

Published: November 27, 2024

Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.

Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.

Journal: Cancers

Published: June 11, 2024

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Journal: Breast cancer research : BCR

Published: April 17, 2024

Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.

Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.

Journal: Current oncology reports

Published: September 26, 2022

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

Journal: EMBO molecular medicine

Published: August 08, 2022

Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.

Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 28, 2021

Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.

Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.

Journal: The breast journal

Published: September 11, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026